92 related articles for article (PubMed ID: 11004693)
1. Relationship between expression of topoisomerase II isoforms and chemosensitivity in choroidal melanoma.
Satherley K; de Souza L; Neale MH; Alexander RA; Myatt N; Foss AJ; Hungerford JL; Hickson ID; Cree IA
J Pathol; 2000 Oct; 192(2):174-81. PubMed ID: 11004693
[TBL] [Abstract][Full Text] [Related]
2. Altered topoisomerase IIalpha and multidrug resistance-associated protein levels during drug selection: adaptations to increasing drug pressure.
Matsumoto Y; Takano H; Nagao S; Fojo T
Jpn J Cancer Res; 2001 Sep; 92(9):968-74. PubMed ID: 11572765
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical expression of topoisomerase IIalpha (Topo IIalpha) and multidrug resistance-associated protein (MRP), plus chemosensitivity testing, as chemotherapeutic indices of ovarian and endometrial carcinomas.
Koshiyama M; Fujii H; Kinezaki M; Morita Y; Nanno H; Yoshida M
Anticancer Res; 2001; 21(4B):2925-32. PubMed ID: 11712788
[TBL] [Abstract][Full Text] [Related]
4. Expression of multidrug-resistance-related proteins P-glycoprotein, glutathione-S-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma.
Shi H; Lu D; Shu Y; Shi W; Lu S; Wang K
Cancer Invest; 2008 May; 26(4):344-51. PubMed ID: 18443954
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of MDR1, LRP, MRP, and topoisomerase IIalpha gene mRNA transcripts before and after interferon-alpha, and correlation with the mRNA expression level of the telomerase subunits hTERT and TEP1 in five unselected human melanoma cell lines.
Miracco C; Maellaro E; Pacenti L; Del Bello B; Valentini MA; Rubegni P; Pirtoli L; Volpi C; Santopietro R; Tosi P
Int J Oncol; 2003 Jul; 23(1):213-20. PubMed ID: 12792796
[TBL] [Abstract][Full Text] [Related]
6. Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta.
Marchion DC; Bicaku E; Turner JG; Daud AI; Sullivan DM; Munster PN
Clin Cancer Res; 2005 Dec; 11(23):8467-75. PubMed ID: 16322310
[TBL] [Abstract][Full Text] [Related]
7. Modulation of DNA topoisomerase II activity and expression in melanoma cells with acquired drug resistance.
Lage H; Helmbach H; Dietel M; Schadendorf D
Br J Cancer; 2000 Jan; 82(2):488-91. PubMed ID: 10646909
[TBL] [Abstract][Full Text] [Related]
8. Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival.
Györffy B; Serra V; Jürchott K; Abdul-Ghani R; Garber M; Stein U; Petersen I; Lage H; Dietel M; Schäfer R
Oncogene; 2005 Nov; 24(51):7542-51. PubMed ID: 16044152
[TBL] [Abstract][Full Text] [Related]
9. Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines.
Rothenborg-Jensen L; Hansen HF; Wessel I; Nitiss JL; Schmidt G; Jensen PB; Sehested M; Jensen LH
Anticancer Drug Des; 2001 Dec; 16(6):305-15. PubMed ID: 12375883
[TBL] [Abstract][Full Text] [Related]
10. Expression of multidrug resistance-related proteins p-glycoprotein, glutathione-s-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma.
Shi H; Lu D; Shu Y; Shi W; Lu S; Wang K
Hepatogastroenterology; 2008; 55(86-87):1530-6. PubMed ID: 19102336
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of karenitecin in patients with malignant melanoma: clinical and translational study.
Daud A; Valkov N; Centeno B; Derderian J; Sullivan P; Munster P; Urbas P; Deconti RC; Berghorn E; Liu Z; Hausheer F; Sullivan D
Clin Cancer Res; 2005 Apr; 11(8):3009-16. PubMed ID: 15837755
[TBL] [Abstract][Full Text] [Related]
12. Predictive value of apoptosis, proliferation, HER-2, and topoisomerase IIalpha for anthracycline chemotherapy in locally advanced breast cancer.
Arpino G; Ciocca DR; Weiss H; Allred DC; Daguerre P; Vargas-Roig L; Leuzzi M; Gago F; Elledge R; Mohsin SK
Breast Cancer Res Treat; 2005 Jul; 92(1):69-75. PubMed ID: 15980993
[TBL] [Abstract][Full Text] [Related]
13. WRC-213, an l-methionine-conjugated mitoxantrone derivative, displays anticancer activity with reduced cardiotoxicity and drug resistance: identification of topoisomerase II inhibition and apoptotic machinery in prostate cancers.
Hsiao CJ; Li TK; Chan YL; Hsin LW; Liao CH; Lee CH; Lyu PC; Guh JH
Biochem Pharmacol; 2008 Feb; 75(4):847-56. PubMed ID: 18035333
[TBL] [Abstract][Full Text] [Related]
14. Differences in the longevity of topo IIalpha and topo IIbeta drug-stabilized cleavable complexes and the relationship to drug sensitivity.
Errington F; Willmore E; Leontiou C; Tilby MJ; Austin CA
Cancer Chemother Pharmacol; 2004 Feb; 53(2):155-62. PubMed ID: 14504921
[TBL] [Abstract][Full Text] [Related]
15. Effect of structural modification at the 4, 3', and 2' positions of doxorubicin on topoisomerase II poisoning, apoptosis, and cytotoxicity in human melanoma cells.
Gruber BM; Anuszewska EL; Bubko I; Goździk A; Fokt I; Priebe W
Arch Immunol Ther Exp (Warsz); 2007; 55(3):193-8. PubMed ID: 17557149
[TBL] [Abstract][Full Text] [Related]
16. DNA topoisomerase I and IIalpha expression in penile carcinomas: assessing potential tumour chemosensitivity.
Berney DM; Stankiewicz E; Adlan AM; Kudahetti S; Biedrzycki OJ; Hadway P; Watkin N; Corbishley C
BJU Int; 2008 Sep; 102(8):1040-4. PubMed ID: 18489530
[TBL] [Abstract][Full Text] [Related]
17. Down-regulation of DNA topoisomerase IIalpha leads to prolonged cell cycle transit in G2 and early M phases and increased survival to microtubule-interacting agents.
Skladanowski A; Côme MG; Sabisz M; Escargueil AE; Larsen AK
Mol Pharmacol; 2005 Sep; 68(3):625-34. PubMed ID: 15942022
[TBL] [Abstract][Full Text] [Related]
18. Expression of p53-induced apoptosis effector PERP in primary uveal melanomas: downregulation is associated with aggressive type.
Paraoan L; Gray D; Hiscott P; Ebrahimi B; Damato B; Grierson I
Exp Eye Res; 2006 Oct; 83(4):911-9. PubMed ID: 16784742
[TBL] [Abstract][Full Text] [Related]
19. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.
Geisler S; Lønning PE; Aas T; Johnsen H; Fluge O; Haugen DF; Lillehaug JR; Akslen LA; Børresen-Dale AL
Cancer Res; 2001 Mar; 61(6):2505-12. PubMed ID: 11289122
[TBL] [Abstract][Full Text] [Related]
20. Correlation between Topo II alpha expression and chemosensitivity testing for Topo II-targeting drugs in gynaecological carcinomas.
Koshiyama M; Fujii H; Kinezaki M; Yoshida M
Anticancer Res; 2001; 21(2A):905-10. PubMed ID: 11396183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
